Comparison between IFNalpha2a + ribavirin and IFNalpha2a + amantadine combination therapy in naive patients with chronic hepatitis C-genotype 1, and between amantadine and ribavirin addition in non responders after 3 months

Autor: Bellobuono, Antonio, Finazzi, R., Covini, G., Milazzo, L., Magni, C., Milella, A.M., Janoletti, C., Bozzetti, F., Bellobuono, Andrea, Idéo, G.
Zdroj: In Journal of Hepatology 2002 36 Supplement 1:98-98
Databáze: ScienceDirect
Externí odkaz: